2022
The Aversive Lens: Stress effects on the prefrontal-cingulate cortical pathways that regulate emotion
Arnsten A, Joyce M, Roberts A. The Aversive Lens: Stress effects on the prefrontal-cingulate cortical pathways that regulate emotion. Neuroscience & Biobehavioral Reviews 2022, 145: 105000. PMID: 36529312, PMCID: PMC9898199, DOI: 10.1016/j.neubiorev.2022.105000.Peer-Reviewed Original ResearchConceptsCortical pathwaysStress exposureDendritic spine lossChronic stress exposureAnti-depressant treatmentDeep brain stimulationPrefrontal cortical areasExcessive dopamineNeuromodulatory treatmentSSRI medicationNorepinephrine releaseSpine lossSubgenual cingulateCortical areasBrain stimulationChronic stressBA25MedicationsDorsolateral PFCTreatmentExposurePsychic painPainKetamineSymptoms
2010
The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder
Arnsten A. The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. Expert Review Of Neurotherapeutics 2010, 10: 1595-1605. PMID: 20925474, PMCID: PMC3143019, DOI: 10.1586/ern.10.133.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderPrefrontal cortexHyperactivity disorderPFC functionPFC gray matterPFC pyramidal cellsPyramidal cell networksDorsolateral prefrontal cortexPFC connectionsReceptors inhibitsPyramidal cellsAdrenergic agonistsDendritic spinesVentromedial prefrontal cortexGray matterRelated disordersBrain regionsNeuropsychiatric disordersPotassium channelsDisordersPatientsRecent dataPhysiological connectionTreatmentExecutive functioning
2005
Chapter 11 Molecular Pharmacology and the Treatment of Tourette's Syndrome and Attention Deficit-Hyperactivity Disorder
Arnsten A. Chapter 11 Molecular Pharmacology and the Treatment of Tourette's Syndrome and Attention Deficit-Hyperactivity Disorder. 2005, 183-iv. DOI: 10.1016/b978-012738903-5/50012-6.Peer-Reviewed Original ResearchAttention deficit hyperactivity disorderDeficit hyperactivity disorderPrefrontal cortexTourette syndromeTherapeutic actionUse of guanfacineΑ2-adrenoceptor agonistNeuropsychiatric symptomsAppropriate medicationNeuromodulatory effectsTourette patientsPostsynaptic sitesNeurochemical environmentNeuropsychiatric illnessBrain circuitsSyndromePFC regulationBasic neuroscienceMolecular pharmacologyMolecular targetsDisordersGuanfacinePatientsPFC functionTreatment